Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment.

Cancer Sci · 2023 · PMC9986061 · PMID 36394119

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

3.7 Biomarker analysis Of the five participants with measurable bone marrow blasts at disease evaluation, two participants showed a trend of decreasing bone marrow blasts.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.